Back to Journals » Neuropsychiatric Disease and Treatment » Volume 10

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Authors Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Received 3 February 2014

Accepted for publication 21 March 2014

Published 16 May 2014 Volume 2014:10 Pages 865—867


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Nobuyoshi Saito, Katsutoshi Shioda, Koichi Nisijima, Toshiyuki Kobayashi, Satoshi Kato

Department of Psychiatry, Jichi Medical University, Tochigi, Japan

Abstract: Electroconvulsive therapy (ECT) is used for medication-resistant and
life-threatening mental disorders, and therefore it occupies an important position in psychiatric treatment. ECT reportedly increases intracranial pressure and is suspected of increasing the risk of intracranial hemorrhage, especially in patients with hemorrhagic diseases such as hemophilia. A decrease in or loss of blood coagulation factors, including factor VIII and factor IX, are found in hemophilia A and B, respectively. Psychiatrists may hesitate to perform ECT on patients with bleeding tendencies, such as in hemophilia. Here, we report the successful use of ECT on a neuroleptic-resistant patient with schizophrenia and severe hemophilia A. We performed ECT 16 times supplemented with coagulation factor VIII to prevent intracranial and systematic hemorrhage. We administered factor VIII concentrates to the patient to keep factor VIII activity at 30%–40% during ECT. The patient did not show bleeding or other complications during the ECT sessions. We suggest that pretreatment with factor VIII can help manage the increased risks of intracranial and systematic bleeding during ECT that is present in patients with hemophilia A. The present report supports the idea of performing ECT safely on patients with hemophilia A by administering factor VIII.

Keywords: ECT, hemorrhagic disease, bleeding

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]